induced pluripotent stem cells

[Advanced Materials] The authors reported a cyborg brain organoid platform, in which “tissue-like” stretchable mesh nanoelectronics are designed to match the mechanical properties of brain organoids and to be folded by the organogenetic process of progenitor or stem cells, distributing stretchable electrode arrays across the 3D organoids.

[Fate Therapeutics, Inc.] Fate Therapeutics, Inc. announced that the US FDA has cleared the company’s Investigational New Drug application for FT536, an off-the-shelf, multiplexed-engineered, iPSC-derived, chimeric antigen receptor NK cell product candidate.

[Century Therapeutics] Century Therapeutics and Bristol Myers Squibb announced a research collaboration and license agreement to develop and commercialize up to four iPSC derived, engineered natural killer cell and / or T cell programs for hematologic malignancies and solid tumors.

[BMC Biology] Researchers investigated the potential of bacteriophage-chimeric retrovirus-like particles for the non-integrative delivery of RNA molecules in human iPSCs for CRISPR/Cas9 applications.

[PLoS Genetics] The authors generated Rothmund-Thomson syndrome (RTS) patient-derived iPSCs to dissect the pathological signaling leading to RTS patient-associated osteosarcoma.

[Stem Cell Reviews and Reports] Researchers described an optimized stepwise protocol to introduce disease-specific mutations of long QT syndrome into human PSCs.